u/mikkel_correia

Asked in my own language at a local pharmacy and got a clearer answer in five minutes than a fortnight of forum reading.

Research-use-only labelling is a description of intended use, not a customs classification. It does not by itself determine how anything is treated at a border.

How long have you been on the list, and from what date?

a certificate with no method line is decorative

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

Agreed — authorisation is European, reimbursement is national, and almost every confused thread here misses that split.

Nothing here is medical or legal advice, and eligibility questions have national answers that a pharmacist where you live can give you in minutes.

This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.

Did they name the facility?

Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.

a 503B has to register and report, so there is a paper trail to ask for

The PDF creation date being later than the analysis date is usually a re-issue or a re-export. It is worth one question and it is not evidence of anything on its own.

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.

That is a packaging observation, not a transit observation. Worth posting, worth separating.

redact your own name, never the batch details